REG - BiVictriX Therapcts. - Total Voting Rights

Bivictrix TherapeuticsAnnouncement

31/08/2021 16:35

RNS Number : 2763K
  
BiVictriX Therapeutics PLC
  
31 August 2021
  
 

 
BiVictriX Therapeutics plc
("BiVictriX" or the "Company")
 
Total Voting Rights
 
 
Alderley Park, UK, 31 August 2021: BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 66,115,201 ordinary shares of 1 pence each with voting rights.
The total number of voting rights in the Company is 66,115,201 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company.
 
For more information, please contact:



BiVictriX Therapeutics plc


 




Tiffany Thorn, Chief Executive Officer


Email: info@bivictrix.com




 








 








SP Angel Corporate Finance LLP (NOMAD and Broker)


Tel: +44 (0) 20 3470 0470




David Hignell, Caroline Rowe (Corporate Finance) 
Vadim Alexandre, Rob Rees (Sales & Broking) 
 








Consilium Strategic Communications


 




Ashley Tapp, Priit Piip


Tel: +44 (0) 20 3709 5700
Email: Bivictrix@consilium-comms.com




 


 

































 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
TVREASPFDDFFEFA